Related Experiment Video
Updated: May 1, 2026

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
Published on: September 18, 2011
Cryptococcal meningitis post autologous stem cell transplantation
1Department of Internal Medicine, University of Kansas School of Medicine-Wichita, Wichita, Kansas, USA.
Abstract:
Disseminated Cryptococcus disease occurs in patients with defective T-cell immunity. Cryptococcal meningitis following autologous stem cell transplant (SCT) has been described previously in only 1 patient, 4 months post SCT and while off antifungal prophylaxis. We present a unique case of Cryptococcus meningitis pre-engraftment after autologous SCT, while the patient was receiving fluconazole prophylaxis. A 41-year-old man with non-Hodgkin's lymphoma underwent autologous SCT. Post-transplant prophylaxis consisted of fluconazole 400 mg daily, levofloxacin 500 mg daily, and acyclovir 800 mg twice daily. On day 9 post transplant, he developed fever and headache. Peripheral white blood cell count (WBC) was 700/μL. Magnetic resonance imaging of the brain showed lesions consistent with meningoencephalitis. Cerebrospinal fluid (CSF) analysis revealed a WBC of 39 with 77% lymphocytes, protein 63, glucose 38, CSF pressure 20.5 cmH2 O, and a positive cryptococcal antigen. CSF culture confirmed Cryptococcus neoformans. The patient was treated with liposomal amphotericin B 5 mg/kg intravenously daily, and flucytosine 37.5 mg/kg orally every 6 h. He was switched to fluconazole 400 mg daily after 3 weeks of amphotericin therapy, with sterilization of the CSF with negative CSFCryptococcus antigen and negative CSF culture. Review of the literature revealed 9 cases of cryptococcal disease in recipients of SCT. Median time of onset was 64 days post transplant. Only 3 meningitis cases were described; 2 of them after allogeneic SCT. Fungal prophylaxis with fluconazole post autologous SCT is recommended at least through engraftment, and for up to 100 days in high-risk patients. A high index of suspicion is needed to diagnose and treat opportunistic infections, especially in the face of immunosuppression and despite adequate prophylaxis. Infection is usually fatal without treatment, thus prompt diagnosis and therapy might be life saving.
Insights
This case highlights early Cryptococcus meningitis in a stem cell transplant (SCT) patient despite fluconazole prophylaxis. Prompt diagnosis and treatment are crucial for survival in these high-risk opportunistic infections.
Area of Science:
- Infectious Diseases
- Hematology
- Oncology
Background:
- Disseminated Cryptococcus disease typically affects individuals with compromised T-cell immunity.
- Cryptococcal meningitis post-autologous stem cell transplant (SCT) is rare, with only one prior reported case occurring months after transplant and without antifungal prophylaxis.
Observation:
- A 41-year-old man with non-Hodgkin's lymphoma developed fever and headache on day 9 post-autologous SCT, while on fluconazole prophylaxis.
- Brain MRI revealed meningoencephalitis, and cerebrospinal fluid (CSF) analysis confirmed Cryptococcus neoformans meningitis with a positive cryptococcal antigen and culture.
- The patient presented with a low white blood cell count (700/μL) and signs of central nervous system infection.
Findings:
- This is the first reported case of Cryptococcus meningitis occurring pre-engraftment after autologous SCT despite continuous fluconazole prophylaxis.
- Literature review identified 9 cases of cryptococcal disease in SCT recipients, with a median onset of 64 days post-transplant; only 3 were meningitis cases, 2 post-allogeneic SCT.
- The patient successfully responded to treatment with liposomal amphotericin B and flucytosine, followed by fluconazole, achieving CSF sterilization.
Implications:
- This case underscores the need for a high index of suspicion for opportunistic infections like Cryptococcus meningitis in immunosuppressed patients, even with adequate prophylaxis.
- Early diagnosis and prompt initiation of appropriate antifungal therapy, such as amphotericin B, are critical for improving outcomes and potentially saving lives in SCT recipients.
- Current recommendations for fungal prophylaxis with fluconazole post-autologous SCT should be considered, especially through engraftment and potentially longer for high-risk individuals.
More Related Videos
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

